KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Payables (2016 - 2025)

Historic Payables for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $14.3 million.

  • Ionis Pharmaceuticals' Payables rose 5826.34% to $14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.3 million, marking a year-over-year increase of 5826.34%. This contributed to the annual value of $43.0 million for FY2024, which is 6507.47% up from last year.
  • Ionis Pharmaceuticals' Payables amounted to $14.3 million in Q3 2025, which was up 5826.34% from $22.8 million recorded in Q2 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Payables peaked at $43.0 million during Q4 2024, and registered a low of $5.6 million during Q3 2023.
  • For the 5-year period, Ionis Pharmaceuticals' Payables averaged around $16.0 million, with its median value being $14.3 million (2025).
  • As far as peak fluctuations go, Ionis Pharmaceuticals' Payables crashed by 7266.97% in 2023, and later skyrocketed by 14667.32% in 2025.
  • Quarter analysis of 5 years shows Ionis Pharmaceuticals' Payables stood at $11.9 million in 2021, then surged by 50.55% to $17.9 million in 2022, then surged by 45.23% to $26.0 million in 2023, then surged by 65.07% to $43.0 million in 2024, then plummeted by 66.66% to $14.3 million in 2025.
  • Its last three reported values are $14.3 million in Q3 2025, $22.8 million for Q2 2025, and $17.5 million during Q1 2025.